AZN's PARP inhibitor meets PFS endpoint in ovarian cancer

An abstract slated for presentation at the upcoming American Society of Clinical Oncology meeting showed olaparib from AstraZeneca plc (LSE:AZN; NYSE:AZN) met the primary endpoint in a Phase II trial ...